PD-L1 Biomarker Testing Market – Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2028

Latest research report on “PD-L1 Biomarker Testing Market” now available at high quality database of ReportsnReports.com with market size, share, trends, competitive and statistical analysis. An exclusive data offered in this report is collected by research and industry experts team.

Get Free Sample Research Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5613528

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to “trick” the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
This report contains market size and forecasts of PD-L1 Biomarker Testing in Global, including the following market information:
Global PD-L1 Biomarker Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global PD-L1 Biomarker Testing market was valued at 1513.1 million in 2021 and is projected to reach US$ 13730 million by 2028, at a CAGR of 37.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
PD-L1 (22C3) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of PD-L1 Biomarker Testing include Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent and Hengrui Medicine and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the PD-L1 Biomarker Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
Global PD-L1 Biomarker Testing Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global PD-L1 Biomarker Testing Market Segment Percentages, by Type, 2021 (%)
– PD-L1 (22C3)
– PD-L1(28-8)
– PD-L1 (SP142)
– PD-L1 (SP263)
– Other
Global PD-L1 Biomarker Testing Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global PD-L1 Biomarker Testing Market Segment Percentages, by Application, 2021 (%)
– Hospital
– Diagnostic Center
– Others
Global PD-L1 Biomarker Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global PD-L1 Biomarker Testing Market Segment Percentages, By Region and Country, 2021 (%)
– North America
– – US
– – Canada
– – Mexico
– Europe
– – Germany
– – France
– – U.K.
– – Italy
– – Russia
– – Nordic Countries
– – Benelux
– – Rest of Europe
– Asia
– – China
– – Japan
– – South Korea
– – Southeast Asia
– – India
– – Rest of Asia
– South America
– – Brazil
– – Argentina
– – Rest of South America
– Middle East & Africa
– – Turkey
– – Israel
– – Saudi Arabia
– – UAE
– – Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies PD-L1 Biomarker Testing revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies PD-L1 Biomarker Testing revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:
– Agilent Technologies
– Roche
– Merck
– Bristol-Myers Squibb
– AstraZeneca
– Ono Pharmaceutical
– Regeneron
– Innovent
– Hengrui Medicine
– Junshi Biosciences

More information about Discount offers (20% or More)  @ https://www.reportsnreports.com/contacts/discount.aspx?name=5613528

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
We provide 24/7 online and offline support to our customers.

E-mail: [email protected]

Phone: +1 888 391 5441

Share This Post

Post Comment